was a of Tim. and joining year afternoon Fiscal thank great Good you, XXXX for for Thank Surmodics. you accomplishment us.
on as headwinds paclitaxel enrollment submitted in application at Mark During SurVeil completed Starting beginning TRANSCEND for year. the schedule and key well. study of with on all the initiatives we year made the debate schedule laid from out on approval we our important the progress we CE the despite the the
the regulatory our first We sirolimus-coated and begin and Sundance for for study we also AVess, both We our drug-coated filed also completed product below-the-knee the for in-human significant balloon our recently of approval access started first drug-coated arteriovenous enrollment advancements for pipeline. in-human balloon to study treatment. to made balloon
think Sublime and we XP pipeline, of Turning to our our I non-drug guide delivery sheath received device. clearance a for coronary our have completed Telemark development radial
an support our the and We in with multinational United to coronary Europe. Telemark signed agreement medical a commercialize catheter partner States device also leading
to orders later our the We have begun from occur and commercial expect initial calendar fill partner to XXXX. in launch
our continue we provide from businesses Medical offerings, initiatives. growth fiscal investment strategic Device in continued our coatings These our generate Finally IVD while substantial revenue strong to operating funding fuel saw in to business margins growth XXXX. to
advancements, as of quarter and million quarter we of to with delivered excellent Total XXXX. a XX% $XX.X revenue topline another compared of these solid As growth in the $XX the quarter result operational million performance. grew for fourth
in also $X.XX earnings share of share We $X.XX non-GAAP per and fourth GAAP of quarter. reported per diluted earnings the
XXXX terrific our The debate it was headwinds While paclitaxel-coated devices under Surmodics surrounding without be a many year within continuing external which fiscal will was not of year its control. challenges. created
including our aware ahead will modality are influence the own we the of drug-coated applications. debate As future balloon that to continue acutely the XXXX, look to we therapeutic paclitaxel
been trials randomized data observational signal mortality of and in the We by a attenuation absence of real-world has of large signal are the recently significant the studies. demonstrate amount encouraged and ongoing from that an complete that very published
some XXXX during This the of advancements, to XXXX. fiscal proud fiscal our goals continuing All unpredictably we to forward look achieve waters team's we'll quite build to our amidst I'm strategic said, that objectives. with ability following achieved and on choppy execute year even the in
the First, to primary endpoint continued high-quality ensure perform patient to for the specifically SurVeil: success analysis. of follow-up
our product the make continue to the pipeline. objective approvals development next to make advances towards is progress and FDA across substantial The achieving meaningful Mark to strategic in product CE approval. key entire and obtain to regulatory Second; of
finally the our strategic initiatives. and revenue to which in businesses Medical continue Devices growth flow fuel from And Diagnostics optimize and cash legacy third both our performance to
with the we Starting very quarter SurVeil, our of in fourth study were planned. as pleased enrollment TRANSCEND clinical to complete
a will evaluate and the compared the efficacy in reminder XXX XX TRANSCEND trial leg. disease of patients arterial enrolled global the drug-coated the commercially at As with and peripheral the treating sites available upper safety DCB SurVeil balloon in
time relevant ultimately provide vascular interventional out and TRANSCEND from at data five clinical very years. for to patient The regarding questions TRANSCEND level community. a clinical will insight data into important comes long-term the
discussion around and high-quality long-term to of focus the monitoring collection patients the paclitaxel follow-up With data. rigorous is of shifting through
TRANSCEND the data the primary analysis stage high-quality be will X-year the the paclitaxel-containing patients Thorough of to primary perform and follow-up rigorous the debate submission. on required of endpoint such, PMA these As the for years and especially five devices. study will through follow-up require given current generate important next past to endpoint
to robust collection this follow-up type to reviewed. clinical committed specific and recently program and ensure data collected thoroughly vital the are that this We data of launched new to a patient
sufficient submission our In regard modules XXXX. on to the for notified to Mark schedule we have receive to Mark body all CE submitted time and European SurVeil, the December required CE by
the the were that long-term decided mortality they ongoing we debate to by notified However, have new review Marks paclitaxel the temporarily body for informed devices signal. considering CE of pause recently given a
completeness DCB. safety has reviewed has body SurVeil, to are generated. Their as stated nothing our file decision performance our decision and that the with do be nor of notified additional of will this The data the
events control, and we of outside supports remain quality of While the the capability our devices and in confident regulatory that our unanticipated the data of such were its approval.
months. body with during dialogue the notified continue to expect coming the fully We this
insurmountable Mark surrounding exclude While of CE EU commercialization previously fiscal to Due an year-end calendar the CE until information. our we any XXXX better we EPS expected. and to from the guidance revenue we've Mark, chosen we mark CE obtain and SurVeil obtaining by impact to the this have from financial the expect XXXX is no do of uncertainty as longer believe setback, timing not that for
recall for strengthening platforms main pipeline. Moving our this three have strategic that to focus our second fiscal we pipeline, within ever XXXX
vascular is and delivery drug-coated Avess balloons first namely; The via SurVeil, drug Sundance.
including The embolism three platform and thrombectomy vascular thrombosis, second and multiple arterial venous beds neovascular in applications. is pulmonary our the thrombosis
third And treatment radial revolutionize and I best to new the care what the health potential access, improved that clinical reduced combining a elements via patient a of Trifecta, has is improved care satisfaction call the of disease by vascular the costs. patient outcomes, frontier
not of platforms team that to of any differentiated At problems. Surmodics, innovate with unique our of create and innovative company spectrum a these size value. shareholder aware meaningful across that solve an differentiated we have to ability develop products I'm broad a can real such
in-house we regulatory Sundance, for our first for the Starting in-human to This .XXX" with balloon approval excipient with leverages on application low yet device our for submitted DCB study pipeline, during initiate proprietary platform, a sirolimus-based PTA quarter DCB our our dose disease. best-in-class our of unique the below-the-knee sirolimus.
a generated of we to the believe the be the data analyzed, field have has Given preclinical product drug-coated balloons. and Sundance potential revolutionary in we
were enrollment granted we the Recently, XXXX. Sundance. the of in back Breakthrough for we Device fiscal to by status start FDA part And expect Designation
arteriovenous We completed also recently study drug-coated first our in-human enrollment for access of balloon. our AVess,
the you first development study from steps six-month And for later year, have We our in by after update in-human from we'll data QX. clinical results the clinical we evaluated in trial. early this next expect AVess the
space. the in are encouraged data shown by We clinical by positive recent other this devices
remain radial platforms access artery we to progress in development non-drug and our And accelerating pipeline, our to of XXXX. fiscal delivery make continue committed platforms. to in thrombectomy Turning the these
We three for XXX(k) least these submit in clearance expect at to platforms. on devices, new
loss. to easy potential use remove organized, Our known peripheral to and has from thrombectomy designed a minimal capital be device blood uniquely to as vessels without pumps and is thrombus equipment
track are the are with fiscal regulatory by XXXX. clearance targeting activities. We on QX And development
Moving XXXX. our second in for clearance XXX(k) of fiscal to Sublime radial FDA guide received on sheath quarter platform, we the our
other secure including our catheter clearance .XXX" balloon transradial radial XXXX. proximal third begun transradial PTA the X.X-meter designed femoropopliteal also more to treat quarter XXX(k) development of expect of access therapeutic devices, And to the PTA .XXX” vessels. We've by the catheter the fiscal long balloon of
sheath. our .XXX" announce products. a and medical complementary start partner, our to an worldwide radial I'm provide early PTA will is line .XXX" commercialization just agreement build of access leading of for Sublime devices balloon the radial we the that, signed week a multinational guide of happy complete with intent our This catheters. this to These device for
identity, the second during request agreed we've withhold partner, At our occur launch to XXXX. of formally their they these will fiscal of until announcing quarter the we expect which products,
Finally, our and IVD to commercial Devices excellence. Medical business drive segments continue
Medical Device business X the faced While due our headwinds expiration technology. year, our this of to hydrophilic-coating segment generation significant
payments from which growth Serene-coating recognition revenue patent our term. and agreement with has as well upfront uptake from to see we are the technology, longer Generation X, continuing of milestone Abbott, the much and a As SurVeil
the low while from excellent margin. business mid-single to immunoassay the Device revenue expirations, Net outperform coating continues Medical Meanwhile, portfolio growth to continues generating in from revenue our of our grow X%, of patent market growth digits. IVD unit the operating the to
Overall our created positioned sound. over matter. business create this And the are we are uncertainty fundamentals shareholder by to despite long-term, value paclitaxel well
basis, greater deliver annual also Our expect of in in goal an will We're remains XXXX. growth margins targeting which XXXX. we revenue on resume to double-digit beginning fiscal fiscal than EBITDA XX%
our Tim fourth to XXXX. as Tim? the for on XXXX outlook more well to as call our turn details quarter now I'll fiscal provide over fiscal results,
